Taiwan TFDA Registry: 52,726 Devices, Import Dependence, and Applicant Concentration

Executive Summary

Taiwan's Food and Drug Administration (TFDA) maintains a publicly accessible medical device registration database covering all Class I, II, and III devices approved for the Taiwanese market. Our analysis of the complete TFDA dataset — 52,726 active device registrations as of June 2026 — reveals a market defined by heavy import dependence and increasing registration volumes.

Key findings: 74.1% of all registered devices are manufactured abroad, with the United States (22.6%), Germany (9.5%), China (8.1%), and Japan (6.4%) as the leading source countries. Domestic Taiwanese manufacturers account for 25.9% of registrations but are concentrated in lower-risk Class I devices (34.3% domestic share) rather than Class III (10.4% domestic share). Class II devices dominate the register at 52.9%, followed by Class I at 41.8% and Class III at 5.2%.

Registration activity peaked at 5,473 new devices in 2021, and has since settled to 2,500–3,400 per year. General Hospital and Plastic Surgery, Dental, and Clinical Chemistry are the three largest specialty areas, each accounting for roughly 10% of the register. The applicant landscape is moderately concentrated — 4,722 unique applicants hold registrations, with the top 10 controlling 14.5%.

This article breaks down the TFDA register by risk class, manufacturing geography, applicant concentration, medical specialty, and annual registration trends — providing regulatory strategists and market-access teams with a quantitative foundation for Taiwan market planning.

Data Source and Methodology

All statistics in this article are derived from our direct analysis of the TFDA Licensed Medical Device Database (public dataset, extracted June 2026). The dataset contains 103,763 total records, of which 52,726 are active (not cancelled) and 51,037 have been cancelled/revoked.

Each record includes: cancellation status, device risk class (級數), manufacturer country, applicant name, manufacturer name, licence issue date, licence expiry date, device sub-category, device main category, and manufacturing process type.

Active devices are identified as records where the cancellation status is not "已註銷" (cancelled). Device class is specified as 1, 2, or 3 corresponding to the TFDA three-tier classification. Manufacturer country was taken directly from the 製造廠國別 field. Applicant concentration was computed using standard Herfindahl-Hirschman Index (HHI) methodology. Percentages are calculated against the total relevant denominator (all 52,726 active records unless otherwise noted).

Taiwan's Regulatory Framework: Why This Market Matters

Taiwan's medical device market is valued at approximately USD 3.2 billion and is projected to grow at a 5.6% CAGR through 2030, with the in-vitro diagnostics segment alone estimated at USD 1.4 billion (8.4% CAGR). The island's National Health Insurance (NHI) system — a single-payer model covering 99.9% of the population — is the dominant procurement channel, making TFDA registration effectively a prerequisite for market access.

TFDA, which celebrated its 15th anniversary in 2025, regulates medical devices under the Medical Devices Act 2021 (replacing the earlier Pharmaceutical Affairs Act provisions). The classification system follows a three-tier framework:

Registration fees are tiered by risk class: Class I costs NT$15,000 (approximately USD 500), Class II costs NT$58,000–60,000 (approximately USD 1,900–2,000), and Class III costs NT$100,000 (approximately USD 3,300). These are government fees only and do not include consulting, dossier preparation, testing, or regulatory representation costs.

TFDA accepts abridged review pathways for devices with prior approval from reference agencies including the US FDA, EU Notified Bodies, and Japan PMDA. As of July 2025, TFDA had published 1,357 recognised standards for medical device evaluation.

Device Class Distribution

The 52,726 active registrations break down as follows:

Three observations stand out:

1. Class II dominates. At 52.9%, Class II devices form the majority of the register, consistent with the global pattern where moderate-risk devices represent the largest segment of most regulatory databases.

2. Import dependence rises with risk class. Class I devices are 65.7% imported, but Class III devices are 89.6% imported — reflecting Taiwan's reliance on foreign manufacturers for high-risk, high-technology medical devices such as implants, cardiac devices, and advanced diagnostic systems.

3. Class III is a small but critical segment. With only 2,716 registrations (5.2%), Class III devices are comparatively rare, consistent with the higher regulatory barriers and longer review timelines for this tier.

Manufacturing Geography: Who Makes Taiwan's Devices

Among 52,726 active registrations, manufacturers are located in 81 countries and territories. The distribution is heavily concentrated:

The top three foreign source countries — the US, Germany, and China — account for 40.2% of all registrations. Together with Japan and South Korea, the top five foreign sources account for 50.3%.

The Import Profile by Risk Class

The foreign-domestic split varies sharply by risk class:

Domestic Taiwanese manufacturers are competitive in Class I devices — basic surgical instruments, contact lenses (Taiwan is a major global contact lens exporter), and hospital supplies — but hold minimal share in Class III, where US and European multinationals dominate. This pattern is consistent with Taiwan's position as a manufacturing hub for mid-technology medical devices while relying on imports for the highest-risk product categories.

Top Product Owners (Manufacturers)

Roche and Siemens together account for 1,184 IVD devices — 2.2% of the entire register. The appearance of Taiwanese manufacturers Ever Victory Optical (a contact lens maker, 339 devices) and TaiDoc Technology (a blood glucose monitoring company, 212 devices) highlights Taiwan's domestic strengths in vision correction and diabetes management devices.

Applicant Concentration: Who Holds the Local Licences

Under Taiwan's regulatory framework, every medical device must be registered through a local applicant (申請商) — a Taiwan-based entity that holds the product licence and serves as the regulatory interface with TFDA. Among 52,726 active registrations, there are 4,722 unique applicants and 12,871 unique manufacturers.

The top applicants are:

Concentration metrics:

• Top 5 applicants: 5,004 devices (9.5%)
• Top 10 applicants: 7,621 devices (14.5%)
• Top 20 applicants: 11,071 devices (21.0%)
• HHI: 37 (low concentration)

The HHI of 37 places this well below the threshold for moderate concentration (HHI > 1,500). The applicant landscape is fragmented and competitive — 4,722 applicants hold an average of 11 registrations each. The dominant applicants are overwhelmingly the local subsidiaries of global medtech companies (Siemens, Medtronic, Roche, Abbott, Boston Scientific, J&J, BD).

Implications for market entry: Foreign manufacturers entering Taiwan typically choose between (1) establishing their own Taiwan subsidiary, (2) appointing a third-party regulatory consulting firm as applicant (such as Klass Consulting, the 6th-largest applicant with 717 registrations), or (3) using a distributor that also serves as applicant. The low HHI suggests a competitive market for regulatory representation services.

Medical Specialty Landscape

The 52,726 devices span TFDA's recognised medical specialty categories. The top categories account for the majority of registrations:

Several observations:

• General/Plastic Surgery leads at 14.0%, a broad category encompassing wound care, surgical instruments, sutures, and aesthetic devices.
• Dentistry (10.7%) is notably large, reflecting Taiwan's high per-capita dental spending and the domestic contact lens and dental materials manufacturing base.
• IVD-related specialties (Clinical Chemistry + Immunology/Microbiology + Hematology/Pathology) collectively account for approximately 20.4% of the register, underscoring Taiwan's importance as an IVD market.
• Ophthalmology (9.0%) reflects Taiwan's position as one of the world's largest contact lens exporters — domestic manufacturers like Ever Victory Optical and St. Shine Optical produce hundreds of registered lens variants.

Registration Trends: Growth Through 2021, Stabilisation After

Annual registration volumes grew substantially from 2015 through 2021 before stabilising:

Several observations:

• The 2021 peak. The 5,473 registrations in 2021 represent the highest annual volume in the dataset, likely driven by pandemic-related demand for diagnostic and protective devices, as well as a backlog of applications being processed after the transition to the Medical Devices Act 2021.
• Post-2021 stabilisation. From 2022 through 2025, annual registrations have settled to 2,500–3,400, consistent with the pre-2019 baseline of 2,200–2,500 plus some organic growth.
• Class III remains steady. High-risk device registrations have held remarkably stable at 190–300 per year across the entire period, suggesting a mature market for regulated Class III devices.
• 2024–2025 uptick. The 2024 (2,884) and 2025 (3,356) figures show a recovery trend, with Class II registrations reaching 1,800 in 2025 — the highest since the 2021 peak.

Taiwan in Context: A High-Tech Island's Device Market

Taiwan's medical device market is shaped by several structural factors:

1. NHI-driven procurement. The National Health Insurance system is the primary payer for medical devices used in clinical settings. NHI reimbursement decisions directly affect device demand. In March 2025, NHI expanded robotic surgery coverage to 17 procedure types, signalling growing adoption of advanced surgical technologies.

2. Domestic manufacturing strengths. Taiwan is a global leader in contact lens manufacturing (Ever Victory Optical, St. Shine Optical, Ginkgo International), blood glucose monitoring (TaiDoc Technology), and increasingly in digital health and AI-enabled diagnostics. TFDA updated its AI/ML CADe/CADx technical guidelines in August 2025, providing a clearer regulatory pathway for AI-powered diagnostic software.

3. Import dependence for advanced devices. The data confirms that Taiwan relies on imports for the highest-risk device categories (89.6% import rate for Class III). US and European multinationals dominate the cardiovascular, orthopaedic implant, and advanced diagnostics segments.

4. Regulatory modernisation. The Medical Devices Act 2021 brought Taiwan's framework closer to international norms, including GHTF-aligned classification and a more structured premarket review process. The American Chamber of Commerce in Taiwan has advocated for faster approval timelines and reform of the Certificate of Free Sale (CFS) / Certificate of Good Manufacturing Practice (CFG) requirement for registration.

5. Cross-strait dynamics. China (8.1% of registrations) is the third-largest source of imported devices, reflecting growing trade in medical devices across the Taiwan Strait, particularly in lower-risk product categories.

Key Takeaways

• 52,726 active device registrations across Class I (41.8%), Class II (52.9%), and Class III (5.2%)
• 74.1% of devices are imported — import dependence rises sharply with risk class, reaching 89.6% for Class III
• US manufacturers hold 22.6% of all registrations; the US, Germany, and China together account for 40.2%
• 4,722 unique applicants with an HHI of 37 — a fragmented, competitive applicant landscape
• Top 10 applicants hold 14.5%, led by Siemens Healthcare Taiwan (1,174) and Medtronic Taiwan (1,129)
• Registration volumes peaked at 5,473 in 2021 and have stabilised at 2,500–3,400 per year
• General/Plastic Surgery, Dentistry, and Clinical Chemistry are the dominant specialty areas
• Domestic strengths in contact lenses, diabetes devices, and dental materials provide a foundation for growth

Data Source

Analysis sample: TFDA Licensed Medical Device Database (public dataset, extracted June 2026), 103,763 total records of which 52,726 are active. Device class based on 醫療器材級數 field. Manufacturing country from 製造廠國別 field. Applicant concentration computed via HHI. Annual registration counts based on licence issue date. All numbers reflect the public register extract and may differ slightly from TFDA's internal records due to timing of data publication.